Technology

W. L. Gore & Associates (Gore) announced that the FDA granted approval for the use of GORE HELEX Septal Occluder with a modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD), providing a percutaneous ASD closure solution for very young patients.

Home February 19, 2008
Home
Feature | Dave Fornell

February 2008 - The traditional hospital cleaning methods of wiping down surfaces and mopping floors are now being ...

Home February 19, 2008
Home
News

February 20, 2008 - Philips Medical Systems features at HIMSS 2008 enhancements to its speech recognition solution ...

Home February 19, 2008
Home
Technology

Toshiba America Medical Systems Inc. recently introduced its Infinix VF-i/SP X-ray system, a universal cardiovascular ...

Home February 19, 2008
Home
Technology

The ACUSON X300 works to provide compact, portable color Doppler solutions for adult, pediatric, OR, EP and ...

Home February 19, 2008
Home
News

February 20, 2008 - At HIMSS 2008, Siemens Healthcare will emphasize its image data management solutions for radiology ...

Home February 19, 2008
Home
Technology

Siemens Medical Solutions received FDA 510(k) clearance for a 1.5T magnetic resonance imaging (MRI) system that is ...

Home February 19, 2008
Home
News

February 19, 2008 – The American College of Cardiology (ACC) urges the medical community to oppose cuts to medical ...

Home February 18, 2008
Home
News

February 19, 2008 - Boston Scientific Corp. closed the sale of its Fluid Management and Venous Access businesses to ...

Home February 18, 2008
Home
News

February 19, 2008 - A new study released today found pending congressional legislation seeking the mandatory disclosure ...

Home February 18, 2008
Home
News

February 19, 2008 - Among patients with acute myocardial infarction (AMI), prior statin therapy is associated with better perfusion after primary angioplasty of the infarct-related artery, according to a report in the January 15 issue of the American Journal of Cardiology.

Home February 18, 2008
Home
News

February 19, 2008 – The first CE certified Nobori Drug-Eluting Coronary Stent System was successfully implanted in Europe, as Terumo Corp. is poised to expand the product from spring 2008 to more than 20 countries in Europe, Asia, New Zealand and Africa.

Home February 18, 2008
Home
News

February 19, 2008 - A regimen of aspirin, clopidogrel and coumadin started at discharge decreased mortality and major adverse cardiac events (MACE) while keeping bleeding to acceptable levels in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with stent placement, reports a study in the February 26, 2008 issue of the Journal of the American College of Car

Home February 18, 2008
Home
News

February 19, 2008 – A novel, fully bioabsorbable salicylate-based stent offers the potential to reduce adverse events associated with current drug-eluting stents (DES) and could be very beneficial to patients with coronary heart disease, according to a presentation at the Cardiovascular Revascularization Therapies 2008 (CRT) symposium.

Home February 18, 2008
Home
News

February 19, 2008 – Clinicians implanted the BioMatrix drug-eluting stent system into the first European patients in a live broadcast during the Joint Interventional Meeting (JIM), held in Rome, Italy, from February 13-15. The BioMatrix drug-eluting stent system, by Biosensors International Group Ltd., combines a biodegradable PLA and the company’s proprietary limus drug, Biolimus A9.

Home February 18, 2008
Home
Subscribe Now